Thalidomide for the Treatment of Thrombocytopenia and Hypersplenism in Patients With Cirrhosis or Thalassemia
Hypersplenism and thrombocytopenia are common complications of liver cirrhosis or thalassemia, but current treatment strategies are limited. This study aimed to evaluate the efficacy and safety of thalidomide in the treatment of hypersplenism and thrombocytopenia in patients with liver cirrhosis or...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-07-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.01137/full |
| _version_ | 1818275357094051840 |
|---|---|
| author | Yaocheng Chen Ning Cai Yongrong Lai Weiwei Xu Jinyan Li Lan Huang Ying Huang Meiling Hu Huangju Yang Jiangming Chen |
| author_facet | Yaocheng Chen Ning Cai Yongrong Lai Weiwei Xu Jinyan Li Lan Huang Ying Huang Meiling Hu Huangju Yang Jiangming Chen |
| author_sort | Yaocheng Chen |
| collection | DOAJ |
| description | Hypersplenism and thrombocytopenia are common complications of liver cirrhosis or thalassemia, but current treatment strategies are limited. This study aimed to evaluate the efficacy and safety of thalidomide in the treatment of hypersplenism and thrombocytopenia in patients with liver cirrhosis or thalassemia. A total of 31 patients with hepatic cirrhosis (n=19) or thalassemia (n=12) diagnosed with hypersplenism and thrombocytopenia (platelet count [PLT] <100×109/L) were included in this prospective cohort study between January 2015 and May 2017. Patients were treated with thalidomide (150–200 mg/d) plus conventional therapy. Spleen length, PLT, leukocyte count (WBC), absolute neutrophil count (ANC), and hemoglobin level (Hb) were measured at baseline, 3, 6, and 12 months. Any adverse events were noted. All of the 31 patients were showed a progressive increase PLT during the 12-month follow-up, and similar results were obtained when subgroup analyses were performed based on the primary disease (cirrhosis or thalassemia). WBC, ANC, and Hb also increased progressively during the 12-month follow-up. Spleen length decreased progressively during the follow-up. No serious adverse events occurred. Thalidomide is a potential treatment for thrombocytopenia caused by hypersplenism in patients with cirrhosis or thalassemia. |
| first_indexed | 2024-12-12T22:28:28Z |
| format | Article |
| id | doaj.art-494262d15c8c4e4ab313d6cdf731f9a3 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-12T22:28:28Z |
| publishDate | 2020-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-494262d15c8c4e4ab313d6cdf731f9a32022-12-22T00:09:41ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-07-011110.3389/fphar.2020.01137498331Thalidomide for the Treatment of Thrombocytopenia and Hypersplenism in Patients With Cirrhosis or ThalassemiaYaocheng Chen0Ning Cai1Yongrong Lai2Weiwei Xu3Jinyan Li4Lan Huang5Ying Huang6Meiling Hu7Huangju Yang8Jiangming Chen9Department of Haematology, Wuzhou Gongren Hospital, Wuzhou, ChinaDepartment of Haematology, Wuzhou Gongren Hospital, Wuzhou, ChinaDepartment of Haematology, The First Affifiliated Hospital of Guangxi Medical University, The First Affiliated Hospital of Guangxi Medical University, Nanning, ChinaDepartment of Haematology, Wuzhou Gongren Hospital, Wuzhou, ChinaDepartment of Haematology, Wuzhou Gongren Hospital, Wuzhou, ChinaDepartment of Haematology, Wuzhou Gongren Hospital, Wuzhou, ChinaDepartment of Haematology, Wuzhou Gongren Hospital, Wuzhou, ChinaDepartment of Haematology, Wuzhou Gongren Hospital, Wuzhou, ChinaDepartment of Haematology, Wuzhou Gongren Hospital, Wuzhou, ChinaDepartment of Haematology, Wuzhou Gongren Hospital, Wuzhou, ChinaHypersplenism and thrombocytopenia are common complications of liver cirrhosis or thalassemia, but current treatment strategies are limited. This study aimed to evaluate the efficacy and safety of thalidomide in the treatment of hypersplenism and thrombocytopenia in patients with liver cirrhosis or thalassemia. A total of 31 patients with hepatic cirrhosis (n=19) or thalassemia (n=12) diagnosed with hypersplenism and thrombocytopenia (platelet count [PLT] <100×109/L) were included in this prospective cohort study between January 2015 and May 2017. Patients were treated with thalidomide (150–200 mg/d) plus conventional therapy. Spleen length, PLT, leukocyte count (WBC), absolute neutrophil count (ANC), and hemoglobin level (Hb) were measured at baseline, 3, 6, and 12 months. Any adverse events were noted. All of the 31 patients were showed a progressive increase PLT during the 12-month follow-up, and similar results were obtained when subgroup analyses were performed based on the primary disease (cirrhosis or thalassemia). WBC, ANC, and Hb also increased progressively during the 12-month follow-up. Spleen length decreased progressively during the follow-up. No serious adverse events occurred. Thalidomide is a potential treatment for thrombocytopenia caused by hypersplenism in patients with cirrhosis or thalassemia.https://www.frontiersin.org/article/10.3389/fphar.2020.01137/fullthalidomidethrombocytopeniahypersplenismthalassemialiver cirrhosis |
| spellingShingle | Yaocheng Chen Ning Cai Yongrong Lai Weiwei Xu Jinyan Li Lan Huang Ying Huang Meiling Hu Huangju Yang Jiangming Chen Thalidomide for the Treatment of Thrombocytopenia and Hypersplenism in Patients With Cirrhosis or Thalassemia Frontiers in Pharmacology thalidomide thrombocytopenia hypersplenism thalassemia liver cirrhosis |
| title | Thalidomide for the Treatment of Thrombocytopenia and Hypersplenism in Patients With Cirrhosis or Thalassemia |
| title_full | Thalidomide for the Treatment of Thrombocytopenia and Hypersplenism in Patients With Cirrhosis or Thalassemia |
| title_fullStr | Thalidomide for the Treatment of Thrombocytopenia and Hypersplenism in Patients With Cirrhosis or Thalassemia |
| title_full_unstemmed | Thalidomide for the Treatment of Thrombocytopenia and Hypersplenism in Patients With Cirrhosis or Thalassemia |
| title_short | Thalidomide for the Treatment of Thrombocytopenia and Hypersplenism in Patients With Cirrhosis or Thalassemia |
| title_sort | thalidomide for the treatment of thrombocytopenia and hypersplenism in patients with cirrhosis or thalassemia |
| topic | thalidomide thrombocytopenia hypersplenism thalassemia liver cirrhosis |
| url | https://www.frontiersin.org/article/10.3389/fphar.2020.01137/full |
| work_keys_str_mv | AT yaochengchen thalidomideforthetreatmentofthrombocytopeniaandhypersplenisminpatientswithcirrhosisorthalassemia AT ningcai thalidomideforthetreatmentofthrombocytopeniaandhypersplenisminpatientswithcirrhosisorthalassemia AT yongronglai thalidomideforthetreatmentofthrombocytopeniaandhypersplenisminpatientswithcirrhosisorthalassemia AT weiweixu thalidomideforthetreatmentofthrombocytopeniaandhypersplenisminpatientswithcirrhosisorthalassemia AT jinyanli thalidomideforthetreatmentofthrombocytopeniaandhypersplenisminpatientswithcirrhosisorthalassemia AT lanhuang thalidomideforthetreatmentofthrombocytopeniaandhypersplenisminpatientswithcirrhosisorthalassemia AT yinghuang thalidomideforthetreatmentofthrombocytopeniaandhypersplenisminpatientswithcirrhosisorthalassemia AT meilinghu thalidomideforthetreatmentofthrombocytopeniaandhypersplenisminpatientswithcirrhosisorthalassemia AT huangjuyang thalidomideforthetreatmentofthrombocytopeniaandhypersplenisminpatientswithcirrhosisorthalassemia AT jiangmingchen thalidomideforthetreatmentofthrombocytopeniaandhypersplenisminpatientswithcirrhosisorthalassemia |